Comparison of histopathological and immunohistochemical features of fibroadenoma and low-grade phyllodes tumor
Article Sidebar
Main Article Content
Abstract
Objective: To evaluate the utility of immunohistochemical (IHC) markers—CD10, CD117, Ki-67, and p53—in differentiating fibroadenoma (FA) from low-grade phyllodes tumors (LGPTs) in breast biopsies.
Methods: This cross-sectional study was conducted at Dow Diagnostic Reference and Research Laboratory (DDRRL), Karachi, from July to December 2023, following ethical approval (IRB-3052/DUHS/Approval/2023/222). A total of 94 breast biopsies (47 FA and 47 LGPTs) were included. Samples with invasive carcinoma, incomplete data, or lack of consent were excluded. Histological diagnosis was made on H&E-stained paraffin sections, followed by IHC analysis using CD10, CD117, Ki-67, and p53 markers. Expression was evaluated using an immunoreactivity score based on staining intensity and percentage of positive cells. Expression intensity was categorized into four levels: +3 (strong), +2 (moderate), +1 (weak), or 0 (no expression). Statistical analysis was performed using SPSS version-26.0.
Results: Mean age was 31.7±9.2 years for FA and 35.2±10.8 years for LGPTs, with significantly larger tumor size in LGPTs (6.4±3.8 cm) than FA (3.3±1.9 cm). Morphologically, stromal hypercellularity, nuclear atypia, and leaf-like architecture were predominantly noted in LGPTs. Immunohistochemically, LGPTs showed higher moderate-to-strong expression of p53 (17 vs. 8 cases, p=0.043), Ki-67 (13 vs. 4 cases, p=0.050), CD117 (19 vs. 8 cases, p=0.024), and CD10 (8 vs. 1 case, p=0.046), compared to FA. LGPTs consistently exhibit higher proportions of moderate to strong stromal expression across all evaluated markers.
Conclusion: Immunohistochemical markers CD10, CD117, Ki-67, and p53 demonstrate significant differential expression between FA and LGPTs. Their combined use can enhance diagnostic accuracy in distinguishing fibroepithelial breast lesions.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Work published in KMUJ is licensed under a
Creative Commons Attribution 4.0 License
Authors are permitted and encouraged to post their work online
(e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
References
1. Lissidini G, Mulè A, Santoro A, Papa G, Nicosia L, Cassano E, et al. Malignant phyllodes tumor of the breast: a systematic review. Pathologica 2022;114(2):111. https://doi.org/10.32074/1591-951X-754
2. Tan PH. Fibroepithelial lesions revisited: implications for diagnosis and management. Mod Pathol 2021;34:15-37. https://doi.org/10.1038/s41379-020-0583-3
3. Lerwill MF, Lee AH, Tan PH. Fibroepithelial tumours of the breast—a review. Virchows Archiv 2022:1-19. https://doi.org/10.1007/s00428-021-03175-6
4. Tan BY, Tan PH. A diagnostic approach to fibroepithelial breast lesions. Surg Pathol Clin 2018;11(1):17-42. https://doi.org/10.1016/j.path.2017.09.003
5. Shubham S, Ahuja A, Bhardwaj M. Immunohistochemical expression of Ki-67, p53, and CD10 in phyllodes tumor and their correlation with its histological grade. J Lab Physicians 2019;11(04):330-4. https://doi.org/10.4103/JLP.JLP_106_19
6. Rivero L, Graudenz M, Aschton-Prolla P, Delgado A, Kliemann L. Accuracy of p53 and ki-67 in the graduation of phyllodes tumor, a model for practical application. Surg Exp Pathol 2020;3:1-8. https://doi.org/10.1186/s42047-020-0058-3
7. Shin E, Koo JS. Prognostic factors of breast phyllodes tumors. Histol Histopathol 2023;38(8):865-78. https://doi.org/10.14670/HH-18-600
8. Louhichi T, Saad H, Dhiab MB, Ziadi S, Trimeche M. Stromal CD10 expression in breast cancer correlates with tumor invasion and cancer stem cell phenotype. BMC Cancer 2018;18:1-9. https://doi.org/10.1186/s12885-017-3951-8
9. Kulkarni MM, Khandeparkar SGS, Joshi AR, Kothikar V, Nasare A, Patil S, et al. Role of CD10 immuno-expression in grading phyllodes tumour of the breast. J Clin Diagn Res 2017;11(1):EC14. https://doi.org/10.7860/JCDR/2017/25613.9231
10. Jana SH, Jha BM, Patel C, Jana D, Agarwal A. CD10-a new prognostic stromal marker in breast carcinoma, its utility, limitations and role in breast cancer pathogenesis. Indian J Pathol Microbiol 2014;57(4):530. https://doi.org/10.4103/0377-4929.142639
11. Jahangir S, Loya A, Mushtaq S, Akhter N, Hashmi AA. CD117/c-KIT expression in phyllodes tumor of the breast and its correlation with morphology and clinical outcome. Cureus 2021;13(5):14914. https://doi.org/10.7759/cureus.14914
12. Lebel E, Nachmias B, Pick M, Gross Even-Zohar N, Gatt ME. Understanding the bioactivity and prognostic implication of commonly used surface antigens in multiple myeloma. J Clin Med 2022;11(7):1809. https://doi.org/10.3390/jcm11071809
13. Wu C-E, Tzen C-Y, Wang S-Y, Yeh C-N. Clinical diagnosis of gastrointestinal stromal tumor (GIST): from the molecular genetic point of view. Cancers 2019;11(5):679. https://doi.org/10.3390/cancers11050679
14. Zhang L, Yang C, Pfeifer JD, Caprioli RM, Judd AM, Patterson NH, et al. Histopathologic, immunophenotypic, and proteomics characteristics of low-grade phyllodes tumor and fibroadenoma: more similarities than differences. NPJ Breast Cancer 2020;6(1):27. https://doi.org/10.1038/s41523-020-0169-8
15. Kasimsetty CR, Deeparani T. Assessment of Ki-67 expression in phyllodes tumor of breast: an Indian study. IP J Diagn Pathol Oncol 2024;9(1):1-8. https://doi.org/10.18231/j.jdpo.2024.001
16. Ali NAM, Nasaruddin AF, Mohamed SS, Rahman WFW. Ki67 and P53 expression in relation to clinic-pathological features in phyllodes tumour of the breast. Asian Pac J Cancer Prev 2020;21(9):2653. https://doi.org/10.31557/APJCP.2020.21.9.2653
17. Tian F, Zhao J, Shi Q-F, Zhang D-C, Wang Y-Y, Sun J-P, et al. Association between CD10 expression andphyllodes tumor: A retrospective case control study. Medicine 2023;102(44):e35677. https://doi.org/10.1097/MD.0000000000035677
18. Puri V, Jain M, Mahajan G, Pujani M. Critical appraisal of stromal CD10 staining in fibroepithelial lesions of breast with a special emphasis on expression patterns and correlation with WHO grading. J Cancer Res Ther 2016;12(2):667-70. https://doi.org/10.4103/0973-1482.177215
19. Vilela MHT, de Almeida FM, de Paula GM, Ribeiro NB, Cirqueira MB, Silva ALP, et al. Utility of Ki-67,CD10, CD34, p53, CD117, and mast cell content in the differential diagnosis of cellular fibroadenomas and in the classification of phyllodes tumors of the breast. Int J Surg Pathol 2014;22(6):485-91. https://doi.org/10.1177/1066896914521290
20. Al-Masri M, Darwazeh G, Sawalhi S, Mughrabi A, Sughayer M, Al-Shatti M. Phyllodes tumor of the breast: role of CD10 in predicting metastasis. Ann Surg Oncol 2012;19:1181-4. https://doi.org/10.1245/s10434-011-2076-6